News

Horizon teams up with AstraZeneca
Enlarge image

BusinessSwedenUK

Horizon teams up with AstraZeneca

23.04.2013 - AstraZeneca has exclusively licenced Horizon Discovery's kinase target programme.

Horizon Discovery and AstraZeneca have entered into an exclusive collaboration and license agreement to explore Horizon's first-in-class kinase target programme, HD-001, as a means of developing novel therapies for multiple cancer types. HD-001 modulates a novel kinase, which is mutated in multiple cancer types including  lung and colon tumours. What is more, the target seems to be crucial in cells with K-RAS mutations, which have been found in 40% of all  cancers that have become resistant to available therapeutics.

The companies said that the preclinical programme have the potential for a  blockbuster drugs as K-RAS defective cells are currently not druggable. Under the terms of the agreement, Horizon will receive undisclosed upfront and preclinical milestone payments, and are eligible for clinical and approval milestones totalling up to US$75m, as well as tiered royalties.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-02/horizon-teams-up-with-astrazeneca.html

GenericsEUUKHungaryGermanyItalyGreeceAustriaLuxembourgFranceSpain

26.02.2015 It is the first biosimilar monoclonal antibody in many European markets: Mundipharma and Hospira are launching Celltrion’s Remicade generic.

M&AUK

23.02.2015 British drug developer Heptares has been acquired by Japanese biopharma play Sosei for US$400m (€352m).

bioethanolGermanyUKBelgiumFrance

19.02.2015 The price of oil has been sliding for months, and the European bioethanol market is taking it hard. CropEnergies AG has now stopped production at its British unit Ensus UK.

BusinessFranceGermany

17.02.2015 After Christopher Viehbacher’s unceremonious ousting last year, Sanofi has been on the look out for a new CEO. Now, sources say Bayer’s Olivier Brandicourt is set to fill the position.

BusinessUKSwitzerland

12.02.2015 Glaxosmithkline is intent on bolstering its vaccine portfolio further and has bought all shares of Swiss development partner Glycovaxyn.

InvestmentsUKEU

10.02.2015 Interest in biotechnology is on the rise among British investors. Not just one, but two major financiers are planning investment funds in the field.

IVFUKEU

04.02.2015 In a historic move, the UK is set to become the first country to allow the creation of babies with the genetic material of three people – a mother, a father and a female mitochondrial donor.

Events

All Events

Partner-Events

Planegg/Martinsried

1st Munich Biotech Pitch

Berlin (DE)

Proteomic Forum 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • WILEX3.43 EUR13.20%
  • EVOLVA1.55 CHF4.73%
  • BASILEA122.20 CHF4.44%

FLOP

  • MOLOGEN5.38 EUR-4.78%
  • BIOFRONTERA1.84 EUR-3.16%
  • MORPHOSYS74.76 EUR-3.01%

TOP

  • WILEX3.43 EUR72.4%
  • FORMYCON16.70 EUR20.1%
  • BASILEA122.20 CHF17.0%

FLOP

  • BIOFRONTERA1.84 EUR-8.9%
  • SANTHERA94.55 CHF-8.2%
  • ADDEX3.20 CHF-7.0%

TOP

  • SANTHERA94.55 CHF2336.9%
  • WILEX3.43 EUR481.4%
  • FORMYCON16.70 EUR106.7%

FLOP

  • CYTOS0.34 CHF-88.7%
  • MOLOGEN5.38 EUR-55.7%
  • BIOFRONTERA1.84 EUR-53.3%

No liability assumed, Date: 26.02.2015